(EXE) Extendicare - Ratings and Ratios
Exchange: TO • Country: Canada • Currency: CAD • Type: Common Stock • ISIN: CA30224T8639
EXE: Long Term Care, Home Health Care, Nursing Services
Extendicare Inc., through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as management, consulting, and other services to third parties. It operates through the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Partner Network brands. The company was incorporated in 1968 and is based in Markham, Canada. Web URL: https://www.extendicare.com
Additional Sources for EXE Stock
EXE Stock Overview
| Market Cap in USD | 587m |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| GiC Sub-Industry | Health Care Facilities |
| IPO / Inception |
EXE Stock Ratings
| Growth 5y | 99.0% |
| Fundamental | 23.6% |
| Dividend | 82.4% |
| Rel. Strength Industry | 3007 |
| Analysts | - |
| Fair Price Momentum | 20.33 CAD |
| Fair Price DCF | 30.06 CAD |
EXE Dividends
| Dividend Yield 12m | 28.40% |
| Yield on Cost 5y | 669.77% |
| Annual Growth 5y | 43.10% |
| Payout Consistency | 75.2% |
EXE Growth Ratios
| Growth Correlation 3m | 55.9% |
| Growth Correlation 12m | 96.7% |
| Growth Correlation 5y | 98.2% |
| CAGR 5y | 88.42% |
| CAGR/Mean DD 5y | 10.19 |
| Sharpe Ratio 12m | 2.48 |
| Alpha | 87.46 |
| Beta | 0.56 |
| Volatility | 29.66% |
| Current Volume | 168.5k |
| Average Volume 20d | 106.7k |
What is the price of EXE stocks?
As of January 22, 2025, the stock is trading at CAD 10.14 with a total of 168,477 shares traded.
Over the past week, the price has changed by -1.65%, over one month by -0.98%, over three months by +18.41% and over the past year by +104.11%.
As of January 22, 2025, the stock is trading at CAD 10.14 with a total of 168,477 shares traded.
Over the past week, the price has changed by -1.65%, over one month by -0.98%, over three months by +18.41% and over the past year by +104.11%.
Is Extendicare a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Extendicare is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 23.58 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EXE as of January 2025 is 20.33. This means that EXE is currently undervalued and has a potential upside of +100.49% (Margin of Safety).
Neither. Based on ValueRay Fundamental Analyses, Extendicare is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 23.58 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EXE as of January 2025 is 20.33. This means that EXE is currently undervalued and has a potential upside of +100.49% (Margin of Safety).
Is EXE a buy, sell or hold?
Extendicare has no consensus analysts rating.
Extendicare has no consensus analysts rating.
What are the forecast for EXE stock price target?
According to ValueRays Forecast Model, EXE Extendicare will be worth about 22 in January 2026. The stock is currently trading at 10.14. This means that the stock has a potential upside of +116.47%.
According to ValueRays Forecast Model, EXE Extendicare will be worth about 22 in January 2026. The stock is currently trading at 10.14. This means that the stock has a potential upside of +116.47%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 11 | 8.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 22 | 116.5% |